2018 Society of Toxicologic Pathology BAY AREA REGIONAL MEETING
DECEMBER 14th FREE 8AM-NOON

Speakers:
Sven Kronenberg, Roche
Charley Dean, Amgen
Ben Hock, BioMarin & Soumi Gupta, BioMarin

Registration required!
1120 Veterans Blvd AMGEN South San Francisco
Questions? Contact Sarav at skaliyap@amgen.com
## Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am</td>
<td>Arrival and light breakfast</td>
</tr>
<tr>
<td>8:30am</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 8:40am | “Immune complex mediated findings in monkey studies with biotherapeutics: findings, mitigation, and implications on clinical trials and regulatory interactions”  
Sven Kronenberg, PhD, DABT, ERT; Roche |
| 9:40am | “Pathobiology of immune complex disease”  
Charley Dean, DVM, PhD, DACVP; Amgen |
| 10:40am| Break                                                                  |
| 11:00am| “ADA testing and insights into hypersensitivity”  
Ben Hock, PhD; BioMarin  
“Maturation of the ADA response and a concomitant decline in circulating immune complexes & associated complement activation is associated with reduced hypersensitivity and increased efficacy of prevails”  
Soumi Gupta, PhD; BioMarin |
| Noon   | Adjourn                                                                |

## Short Speaker Biographies

Sven Kronenberg, MSc, PhD, DABT, ERT is a toxicologist at Roche with almost 20 years of professional experience in non-clinical safety (NCS) testing in the pharmaceutical industry. He received his PhD from Heinrich-Heine University & Environmental Health Research Institute (IUF), Düsseldorf. He has extensive experience with small molecule and biotherapeutic drug development, including immune complex-mediated hypersensitivity reactions.

Charley Dean, DVM, PhD, DACVP is a veterinary pathologist at Amgen with >15 years of experience in Biopharma. He received his DVM from the Oregon State/Washington State University program and completed his PhD and Pathology Residency at Colorado State University. He has extensive experience with immunogenicity of biologics particularly Anti-Drug Antibody Immune Complex Disease (ADA-IC) and its impact on drug development.

Ben Hock, PhD is Director of Immunogenicity at BioMarin with nearly 15 years of experience. He received his PhD from Emory University. His career began at the bench developing and validating immunoassay methods and has transitioned to focusing on the relationship between specific bioanalytical methods and the clinically-relevant questions/hypotheses those methods are designed to address.

Soumi Gupta, PhD is Director of Immunogenicity at BioMarin with >15 years of experience in immunology and infectious disease, vaccinology, HIV drug resistance, oncology diagnostics and drug development. She received her PhD from UC Davis. She provides immunologic expertise to drug programs across developmental stages and develops immunogenicity and safety strategies for novel biologic therapeutics. Most recently, she led the immunogenicity assessment strategy, data analysis and interpretation for a PEGylated enzyme replacement therapy, instrumental to its approval for the treatment of PKU in adults in the US.